Six months' treatment with lifitegrast in patients with moderate-to-severe symptomatic dry eye: a retrospective chart review

Figures & data

Figure 1 Patient age distribution of the chart review.

Figure 2 Baseline dry eye symptoms (blue bars) and clinical signs (yellow bars).

Figure 3 Improvement in patient-reported symptoms after 6-month treatment with lifitegrast.

Notes: Patients were asked to rate the overall improvement of their eye symptoms at the 6-month visit. Treatment effects were categorized into the 4 categories using a VAS: 0 as no improvement; 1–3 as minor improvement; 4–6 as moderate improvement and 7–10 as significant improvement. See Patients and methods section.

Table 1 Improvement of clinical signs from baseline after 6-month treatment with lifitegrast

Evaluated clinical signs	Improvement from baseline n (improved)/n (baseline) (%)
Superficial punctate keratitis	142/142 (100)
Conjunctival staining	27/27 (100)
Conjunctival hyperemia	138/161 (85)
Presence of tear debris	37/50 (74)
Increased tear meniscus	14/116 (12)

Table 2 Summary of most reported (>5%) adverse events

Most frequent adverse event	Lifitegrast-treated patients, n (%) n=168
Bad taste (dysgeusia)	28 (16)
Blurry vision	16 (9.5)
Burning	13 (7)
Installation site reaction	11 (6.5)
Eye irritation	12 (7)
Transient redness	14 (8.3)
Eye discomfort	12 (7)
Eye irritation	12 (7)

Note: Patients were asked to report 12 categories of adverse events, see Patients and methods section.